Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: Results from a randomized clinical trial

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Houschyar, Khosrow S ^a   Lüdtke, Rainer ^b   Dobos, Gustav J ^a   Kalus, Ulrich ^c   Broecker Preuss, Martina ^d   Rampp, Thomas ^a   Brinkhaus, Benno ^c   Michalsen, Andreas ^c,e,f  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Karl und Veronica Carstens Foundation   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e Immanuel Hospital Berlin   (Germany)

^f Department of Internal and Integrative Medicine ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IRON; LIPID;

ADULT; AGED; ARTICLE; BLOOD DONOR; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIZZINESS; DYSLIPIDEMIA; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTENTION TO TREAT ANALYSIS; IRON DEPLETION; IRON STORAGE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATIENT SAFETY; PHLEBOTOMY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HOMEOSTASIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; FEMALE; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; IRON; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHLEBOTOMY; TREATMENT OUTCOME;

EID: 84861547524     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-54     Document Type: Article

References (37)

1. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607. 10.2337/diabetes.37.12.1595, 3056758.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359. 10.1001/jama.287.3.356, 11790215.
3. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004, 164:1066-1076. 10.1001/archinte.164.10.1066, 15159263.
4. Whaley-Connell A, McCullough PA, Sowers JR. The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med 2011, 12:21-29.
5. Coban E, Alkan E, Altuntas S, Akar Y. Serum ferritin levels correlate with hypertensive retinopathy. Med Sci Monit 2010, 16:CR92-95.
6. Piperno A, Trombini P, Gelosa M, Mauri V, Pecci V, Vergani A, Salvioni A, Mariani R, Mancia G. Increased serum ferritin is common in men with essential hypertension. J Hypertens 2002, 20:1513-1518. 10.1097/00004872-200208000-00013, 12172312.
7. Ellervik C, Tybjaerg-Hansen A, Appleyard M, Ibsen H, Nordestgaard BG. Haemochromatosis genotype and iron overload: association with hypertension and left ventricular hypertrophy. J Intern Med 2010, 268:252-264. 10.1111/j.1365-2796.2010.02217.x, 20337854.
8. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999, 22:1978-1983. 10.2337/diacare.22.12.1978, 10587829.
9. Fumeron F, Pean F, Driss F, Balkau B, Tichet J, Marre M, Grandchamp B. Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes Care 2006, 29:2090-2094. 10.2337/dc06-0093, 16936158.
10. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004, 291:711-717. 10.1001/jama.291.6.711, 14871914.
11. Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ 1998, 317:727. 10.1136/bmj.317.7160.727, 28662, 9732340.
12. Wrede CE, Buettner R, Bollheimer LC, Scholmerich J, Palitzsch KD, Hellerbrand C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006, 154:333-340. 10.1530/eje.1.02083, 16452549.
13. Sun L, Franco OH, Hu FB, Cai L, Yu Z, Li H, Ye X, Qi Q, Wang J, Pan A, et al. Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly chinese. J Clin Endocrinol Metab 2008, 93:4690-4696. 10.1210/jc.2008-1159, 18796516.
14. Vari IS, Balkau B, Kettaneh A, Andre P, Tichet J, Fumeron F, Caces E, Marre M, Grandchamp B, Ducimetiere P. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007, 30:1795-1801. 10.2337/dc06-2312, 17416791.
15. Cho GJ, Shin JH, Yi KW, Park HT, Kim T, Hur JY, Kim SH. Serum ferritin levels are associated with metabolic syndrome in postmenopausal women but not in premenopausal women. Menopause 2011, 18:1120-1124. 10.1097/gme.0b013e318217e172, 21694651.
16. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. J Hepatol 2011, 55:1120-1124.
17. Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, Motta BM, Bertelli C, Fatta E, Bignamini D, Rametta R, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011, 21:568-575. 10.1016/j.numecd.2010.01.003, 20392616.
18. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993, 77:478-483. 10.1210/jc.77.2.478, 8345055.
19. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89:739-761.
20. Equitani F, Fernandez-Real JM, Menichella G, Koch M, Calvani M, Nobili V, Mingrone G, Manco M. Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. Diabetes Care 2008, 31:3-8.
21. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002, 51:1000-1004. 10.2337/diabetes.51.4.1000, 11916918.
22. Bofill C, Joven J, Bages J, Vilella E, Sans T, Cavalle P, Miralles R, Llobet J, Camps J. Response to repeated phlebotomies in patients with non-insulin-dependent diabetes mellitus. Metabolism 1994, 43:614-620. 10.1016/0026-0495(94)90204-6, 8177050.
23. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002, 122:931-939. 10.1053/gast.2002.32403, 11910345.
24. Facchini FS, Saylor KL. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 2003, 52:1204-1209. 10.2337/diabetes.52.5.1204, 12716753.
25. Zidek W, Tenschert W, Karoff C, Vetter H. Treatment of resistant hypertension by phlebotomy. Klin Wochenschr 1985, 63:762-764. 10.1007/BF01733828, 4046500.
26. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res 2005, 68:26-36. 10.1016/j.cardiores.2005.06.021, 16009356.
27. Zacharski LR. Hemochromatosis, iron toxicity and disease. J Intern Med 2010, 268:246-248. 10.1111/j.1365-2796.2010.02233.x, 20695974.
28. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, Burdick L, Frugoni C, Fracanzani AL, Fargion S. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2010, 31:683-690.
29. Fleming DJ, Jacques PF, Tucker KL, Massaro JM, D'Agostino RB, Wilson PW, Wood RJ. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. Am J Clin Nutr 2001, 73:638-646.
30. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Wiley Series in Probability and Statistics. 1987, New York: Wiley & Sons.
31. Holm S. A simple sequentially rejective Bonferroni test procedure. Scand J Stat 1979, 6:65-70.
32. Barenbrock M, Spieker C, Rahn KH, Zidek W. Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis. Clin Nephrol 1993, 40:241-243.
33. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665. 10.1136/bmj.b1665, 2684577, 19454737.
34. Pelot D, Zhou XJ, Carpenter P, Vaziri ND. Effects of experimental hemosiderosis on pancreatic tissue iron content and structure. Dig Dis Sci 1998, 43:2411-2414. 10.1023/A:1026669829121, 9824127.
35. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 2007, 297:603-610. 10.1001/jama.297.6.603, 17299195.
36. Challoner T, Briggs C, Rampling MW, Thomas DJ. A study of the haematological and haemorheological consequences of venesection. Br J Haematol 1986, 62:671-678. 10.1111/j.1365-2141.1986.tb04090.x, 3964560.
37. Cinar Y, Demir G, Pac M, Cinar AB. Effect of hematocrit on blood pressure via hyperviscosity. Am J Hypertens 1999, 12:739-743. 10.1016/S0895-7061(99)00011-4, 10411372.